Received Mar 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
shingles twice post vaccination/suspected vaccination failure; shingles twice post vaccination; This serious case was reported by a other health professional via call center representative and described the occurrence of vaccination failure in a 65-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included kidney transplant (on immunosuppressant). On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and Shingrix, the patient experienced vaccination failure (Verbatim: shingles twice post vaccination/suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: shingles twice post vaccination). The outcome of the vaccination failure was not reported and the outcome of the shingles was unknown. It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix. The company considered the vaccination failure to be unrelated to Shingrix and Shingrix. It was unknown if the company considered the shingles to be related to Shingrix and Shingrix. Additional Information: GSK receipt date 26-FEB-2026 The reporter asked if there any scenarios where a booster was indicated after a full series. The patient had gotten shingles twice post vaccination. This case was considered as suspected vaccination failure since the details regarding time to onset and laboratory confirmation of shingles was not reported. The batch number was not provided upon follow- up with the reporter.; Sender's Comments: A case of Vaccination failure, unknown time after receiving 2nd dose of Shingrix and the 1st dose of Shingrix, in a 65-year-old male patient. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Further follow up information has been sought.
Kidney transplant (on immunosuppressant)